CSL
Recommendation
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
CSL recently announced its biotherapies division has been awarded a contract to supply the US government with pre-pandemic and pandemic influenza vaccines. This contract could be worth US$1.5bn if the US takes up its full allocation. This is yet another piece of positive news following on from CSL’s stellar full year results released in August (see CSL: Result 2012 from 23 Aug 12 (Hold – $42.08)).
This company is one of the few businesses that can grow earnings regardless of the economic environment and shareholders shouldn’t consider selling unless they’re offered a very rich price. And with CSL’s share price nearing our ‘Take Part Profits’ price of $45 per share we are increasing our recommendation guide prices to reflect the progress made over the past year, the continued growth opportunities for the business and its extremely high underlying quality. However, if you purchased a significant stake in CSL at much lower prices and it now makes up a large proportion of your portfolio you may consider trimming your holding to within the portfolio limit. The share price has increased 7% since 23 Aug 12 and we’re happy to HOLD.
Note: The Growth portfolio owns shares in CSL.
Recommendation
Call 1300 880 160
Start a chat
Schedule a call
